These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 578254)

  • 21. Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate.
    Tseng A; Jacobs C; Coleman CN; Horning SJ; Lewis BJ; Rosenberg SA
    Cancer Treat Rep; 1987 May; 71(5):475-8. PubMed ID: 3567972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of advanced resistant Hodgkin's disease with lomustine, etoposide, and prednimustine.
    Cervantes F; Reverter JC; Montserrat E; Rozman C
    Cancer Treat Rep; 1986 May; 70(5):665-7. PubMed ID: 3708614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Four cases of Hodgkin's disease treated with MOPP/ABV hybrid regimen using nitrogen mustard-N-oxide hydrochloride].
    Kozai Y; Ohyama T; Kodo H; Tomori G
    Gan To Kagaku Ryoho; 1992 Dec; 19(14):2407-9. PubMed ID: 1281397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
    Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L
    Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Chemotherapy in pretreated Hodgkin's disease with lomustine, bleomycin, vinblastine and dexamethasone].
    Weiss J; von Roemeling R; Peters HD; Schmoll HJ; Diehl V
    Dtsch Med Wochenschr; 1983 Sep; 108(38):1428-32. PubMed ID: 6192987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease.
    Riccardi A; Gobbi P; Danova M; Giordano M; Pieresca C; Bertoloni D; Brugnatelli S; Ascari E
    Haematologica; 1993; 78(1):44-8. PubMed ID: 7684012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
    Canellos GP; Anderson JR; Propert KJ; Nissen N; Cooper MR; Henderson ES; Green MR; Gottlieb A; Peterson BA
    N Engl J Med; 1992 Nov; 327(21):1478-84. PubMed ID: 1383821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies.
    Bloomfield CD; Pajak TF; Glicksman AS; Gottlieb AJ; Coleman M; Nissen NI; Rafla S; Stutzman L; Vinciguerra V; Glidewell OJ; Holland JF
    Cancer Treat Rep; 1982 Apr; 66(4):835-46. PubMed ID: 6176320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Southeastern Cancer Study Group trials with nitrosoureas in Hodgkin's disease.
    Durant JR; Bartolucci A; Gams RA; Dorfman RF; Velez-Garcia E
    Cancer Treat Rep; 1976 Jun; 60(6):781-7. PubMed ID: 782700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
    J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined chemotherapy (MOPP or ABVD)-radiotherapy approach in advanced Hodgkin's disease.
    Bonadonna G; Zucali R; De Lena M; Valagussa P
    Cancer Treat Rep; 1977 Aug; 61(5):769-77. PubMed ID: 70270
    [No Abstract]   [Full Text] [Related]  

  • 33. [Recurrence of Hodgkin's disease after advanced primary stages. German Hodgkin's Study Group].
    Fuchs R; Löffler M; Pfreundschuh M; Dölken G; Gerhartz H; Hagen-Aukamp U; Hiller E; Petsch S; Pflüger KH; Rühl U
    Med Klin (Munich); 1992 Nov; 87(11):555-62. PubMed ID: 1281905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie.
    Raemaekers J; Burgers M; Henry-Amar M; Pinna A; Mandard A; Monfardini S; Hagenbeek A; Breed W; Carde P; Vovk M; van Hoof A; Thomas J; Noordijk E
    Ann Oncol; 1997; 8 Suppl 1():111-4. PubMed ID: 9187443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
    De Lena M; Ditonno P; Lorusso V; Timurian A; Pellecchia A; Brandi M; Berardi F; Marzullo F
    Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An unusual case of spontaneous remission of Hodgkin's disease after a single cycle of COPP-ABV chemotherapy followed by infectious complications.
    Bang SM; Cheong JW; Yang WI; Hahn JS
    Yonsei Med J; 2005 Jun; 46(3):425-30. PubMed ID: 15988816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alternating drug combinations in the treatment of advanced Hodgkin's disease.
    Santoro A; Bonadonna G; Bonfante V; Valagussa P
    N Engl J Med; 1982 Apr; 306(13):770-5. PubMed ID: 6174865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy for bronchogenic carcinoma. Methotrexate, doxorubicin, cyclophosphamide, and lomustine.
    Chahinian PA; Arnold DJ; Cohen JM; Purpora DP; Jaffrey IS; Teirstein AS; Kirschner PA; Holland JF
    JAMA; 1977 May; 237(22):2392-6. PubMed ID: 576939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
    Fermé C; Eghbali H; Meerwaldt JH; Rieux C; Bosq J; Berger F; Girinsky T; Brice P; van't Veer MB; Walewski JA; Lederlin P; Tirelli U; Carde P; Van den Neste E; Gyan E; Monconduit M; Diviné M; Raemaekers JM; Salles G; Noordijk EM; Creemers GJ; Gabarre J; Hagenbeek A; Reman O; Blanc M; Thomas J; Vié B; Kluin-Nelemans JC; Viseu F; Baars JW; Poortmans P; Lugtenburg PJ; Carrie C; Jaubert J; Henry-Amar M;
    N Engl J Med; 2007 Nov; 357(19):1916-27. PubMed ID: 17989384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Third-line chemotherapy with CAVP (CCNU, melphalan, etoposide and prednisone) in refractory Hodgkin's disease.
    Cartoni C; Cimino G; Anselmo AP; Amadori S; Mandelli F
    Haematologica; 1989; 74(3):273-7. PubMed ID: 2511096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.